TRAF1 and pancreatic adenocarcinoma: Conversely, in HNSC (OS: n = 501, p = 0.030, Fig. 3E), mesothelioma (MESO) (OS: n = 84, p = 0.049, Fig. 3F), pancreatic adenocarcinoma (PAAD) (OS: n = 177, p = 0.003, Fig. 3G), and skin cutaneous melanoma (SKCM) (OS: n = 457, p < 0.001, Fig. 3H), TRAF1 expression correlated with a protective effect, indicating its role as a potential inhibitor in these cancer types.